RBC Capital on Sarepta (SRPT): 'KOL Feedback Suggests Elevidys Use Unlikely To Pick Back Up in '26'
Tweet Send to a Friend
RBC Capital analyst Brian Abrahams reiterated a Sector Perform rating and $18.00 price target on Sarepta Therapeutics (NASDAQ: SRPT).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
